Literature DB >> 18580463

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

Shu-Sen Zheng1, Xiao Xu, Jian Wu, Jun Chen, Wei-Lin Wang, Min Zhang, Ting-Bo Liang, Li-Ming Wu.   

Abstract

INTRODUCTION: Liver transplantation (LT) has been the treatment of choice for patients with hepatocellular carcinoma (HCC). This study was designed to summarize our experience in LT for HCC patients and establish a new set of criteria for patient selection and prognosis prediction.
MATERIALS AND METHODS: Data of 195 patients with HCC were retrospectively analyzed and various clinical and pathological factors for survival and tumor-free survival were examined by univariate and multivariate analyses.
RESULTS: Macrovascular invasion, preoperative serum alpha fetoprotein (AFP) level, tumor size, multifocality, histopathologic grading, distribution, and cirrhosis background were significant factors for survival and tumor-free survival by univariate analysis. Multivariate analysis identified macrovascular invasion, tumor size, preoperative AFP level, and histopathologic grading were prognostic factors independently associated with patient survival or tumor-free survival (RR=1.688-2.779, P=0.000-0.034). Based on the prognostic stratification of different risk groups of patients without macrovascular invasion, Hangzhou criteria was established, containing one of the two following items: (a) Total tumor diameter less than or equal to 8 cm; (b) total tumor diameter more than 8 cm, with histopathologic grade I or II and preoperative AFP level less than or equal to 400 ng/mL, simultaneously. The difference between survival curves of patients fulfilling Milan criteria (n=72) and patients fulfilling Hangzhou criteria (n=99) did not achieve statistical significance (5-year survival rates: 78.3% vs. 72.3%, P>0.05). Of the patients exceeding Milan criteria (n=123), those who fulfilled Hangzhou criteria (n=26) also had better prognosis than the others (n=97) (P=0.000).
CONCLUSION: The results of this study show a reliable and feasible candidates selection and prognostic criteria of LT in HCC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18580463     DOI: 10.1097/TP.0b013e31816b67e4

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  178 in total

1.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

2.  Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.

Authors:  Steven-Huy Han; K Rajender Reddy; Emmet B Keeffe; Consuelo Soldevila-Pico; Robert Gish; Raymond T Chung; Bulent Degertekin; Anna Lok
Journal:  Clin Transplant       Date:  2010-11-16       Impact factor: 2.863

3.  Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.

Authors:  Guang-Qin Xiao; Jiu-Lin Song; Shu Shen; Jia-Yin Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Liver transplant for patients outside Milan criteria.

Authors:  Giovanni Battista Levi Sandri; Michel Rayar; Xingshun Qi; Pierleone Lucatelli
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-26

Review 5.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

6.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

7.  "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China.

Authors:  Jian-Yong Lei; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

8.  Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies.

Authors:  Jianyong Lei; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-01-17       Impact factor: 3.452

9.  Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.

Authors:  Dong-Zhi Zhang; Xiao-Dong Wei; Xiao-Peng Wang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 10.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.